Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a ...

New treatment advances are providing a lot of hope, and even a potential cure, for difficult to treat large B-cell lymphoma ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Mr. Zhou, a 63-year-old resident of Shanghai, returned to a hospital for what would become his third fight against diffuse ...